Search

Introduction Disorders of glucose homeostasis affect approximately 50% of patients suffering from chronic kidney disease (CKD) (1-4) and play a major role in their mortality (5, 6). Glucose homeostasis relies [...], Disorders of glucose homeostasis are common in chronic kidney disease (CKD) and are associated with increased mortality, but the mechanisms of impaired insulin secretion in this disease remain unclear. Here, we tested the hypothesis that defective insulin secretion in CKD is caused by a direct effect of urea on pancreatic β cells. In a murine model in which CKD is induced by 5/6 nephrectomy (CKD mice), we observed defects in glucose-stimulated insulin secretion in vivo and in isolated islets. Similarly, insulin secretion was impaired in normal mouse and human islets that were cultured with disease-relevant concentrations of urea and in islets from normal mice treated orally with urea for 3 weeks. In CKD mouse islets as well as ureaexposed normal islets, we observed an increase in oxidative stress and protein O-GlcNAcylation. Protein O-GlcNAcylation was also observed in pancreatic sections from CKD patients. Impairment of insulin secretion in both CKD mouse and urea-exposed islets was associated with reduced glucose utilization and activity of phosphofructokinase 1 (PFK-1), which could be reversed by inhibiting O-GlcNAcylation. Inhibition of O- GlcNAcylation also restored insulin secretion in both mouse models. These results suggest that insulin secretory defects associated with CKD arise from elevated circulating levels of urea that increase islet protein O-GlcNAcylation and impair glycolysis.

The functional mass of insulin-secreting pancreatic β-cells expands to maintain glucose homeostasis in the face of nutrient excess, in part via replication of existing β-cells. Type 2 diabetes appears when these compensatory mechanisms fail. Nutrients including glucose and fatty acids are important contributors to the β-cell compensatory response, but their underlying mechanisms of action remain poorly understood. We investigated the transcriptional mechanisms of β-cell proliferation in response to fatty acids. Isolated rat islets were exposed to 16.7 mmol/L glucose with or without 0.5 mmol/L oleate (C18:1) or palmitate (C16:0) for 48 h. The islet transcriptome was assessed by single-cell RNA sequencing. β-Cell proliferation was measured by flow cytometry. Unsupervised clustering of pooled β-cells identified different subclusters, including proliferating β-cells. β-Cell proliferation increased in response to oleate but not palmitate. Both fatty acids enhanced the expression of genes involved in energy metabolism and mitochondrial activity. Comparison of proliferating versus nonproliferating β-cells and pseudotime ordering suggested the involvement of reactive oxygen species (ROS) and peroxiredoxin signaling. Accordingly, N-acetyl cysteine and the peroxiredoxin inhibitor conoidin A both blocked oleate-induced β-cell proliferation. Our study reveals a key role for ROS signaling through peroxiredoxin activation in oleate-induced β-cell proliferation. [ABSTRACT FROM AUTHOR]

Fatty acid (FA) signaling contributes to β-cell mass expansion in response to nutrient excess, but the underlying mechanisms are poorly understood. In the presence of elevated glucose, FA metabolism is shifted toward synthesis of complex lipids, including sphingolipids. Here, we tested the hypothesis that sphingolipids are involved in the β-cell proliferative response to FA. Isolated rat islets were exposed to FA and 16.7 mmol/L glucose for 48-72 h, and the contribution of the de novo sphingolipid synthesis pathway was tested using the serine palmitoyltransferase inhibitor myriocin, the sphingosine kinase (SphK) inhibitor SKI II, or knockdown of SphK, fatty acid elongase 1 (ELOVL1) and acyl-CoA-binding protein (ACBP). Rats were infused with glucose and the lipid emulsion ClinOleic and received SKI II by gavage. β-Cell proliferation was assessed by immunochemistry or flow cytometry. Sphingolipids were analyzed by liquid chromatography-tandem mass spectrometry. Among the FAs tested, only oleate increased β-cell proliferation. Myriocin, SKI II, and SphK knockdown all decreased oleate-induced β-cell proliferation. Oleate exposure did not increase the total amount of sphingolipids but led to a specific rise in 24:1 species. Knockdown of ACBP or ELOVL1 inhibited oleate-induced β-cell proliferation. We conclude that unsaturated very-long-chain sphingolipids produced from the available C24:1 acyl-CoA pool mediate oleate-induced β-cell proliferation in rats. [ABSTRACT FROM AUTHOR]

The free fatty-acid receptors FFAR1 (GPR40) and FFAR4 (GPR120) are implicated in the regulation of insulin secretion and insulin sensitivity, respectively. Although GPR120 and GPR40 share similar ligands, few studies have addressed possible interactions between these 2 receptors in the control of glucose homeostasis. Here we generated mice deficient in gpr120 (Gpr120KO) or gpr40 (Gpr40KO), alone or in combination (Gpr120/40KO), and metabolically phenotyped male and female mice fed a normal chow or high-fat diet. We assessed insulin secretion in isolated mouse islets exposed to selective GPR120 and GPR40 agonists singly or in combination. Following normal chow feeding, body weight and energy intake were unaffected by deletion of either receptor, although fat mass increased in Gpr120KO females. Fasting blood glucose levels were mildly increased in Gpr120/40KO mice and in a sex-dependent manner in Gpr120KO and Gpr40KO animals. Oral glucose tolerance was slightly reduced in male Gpr120/40KO mice and in Gpr120KO females, whereas insulin secretion and insulin sensitivity were unaffected. In hyperglycemic clamps, the glucose infusion rate was lower in male Gpr120/40KO mice, but insulin and c-peptide levels were unaffected. No changes in glucose tolerance were observed in either single or double knock-out animals under high-fat feeding. In isolated islets from wild-type mice, the combination of selective GPR120 and GPR40 agonists additively increased insulin secretion. We conclude that while simultaneous activation of GPR120 and GPR40 enhances insulin secretion ex vivo, combined deletion of these 2 receptors only minimally affects glucose homeostasis in vivo in mice. [ABSTRACT FROM AUTHOR]

The molecular mechanisms of β-cell compensation to metabolic stress are poorly understood. We previously observed that nutrient-induced β-cell proliferation in rats is dependent on epidermal growth factor receptor (EGFR) signaling. The aim of this study was to determine the role of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) in the β-cell proliferative response to glucose, a β-cell mitogen and key regulator of β-cell mass in response to increased insulin demand. We show that exposure of isolated rat and human islets to HB-EGF stimulates β-cell proliferation. In rat islets, inhibition of EGFR or HB-EGF blocks the proliferative response not only to HB-EGF but also to glucose. Furthermore, knockdown of HB-EGF in rat islets blocks β-cell proliferation in response to glucose ex vivo and in vivo in transplanted glucose-infused rats. Mechanistically, we demonstrate that HB-EGF mRNA levels are increased in β-cells in response to glucose in a carbohydrate-response element-binding protein (ChREBP)-dependent manner. In addition, chromatin immunoprecipitation studies identified ChREBP binding sites in proximity to the HB-EGF gene. Finally, inhibition of Src family kinases, known to be involved in HB-EGF processing, abrogated glucose-induced β-cell proliferation. Our findings identify a novel glucose/HB-EGF/EGFR axis implicated in β-cell compensation to increased metabolic demand. [ABSTRACT FROM AUTHOR]

The pancreatic β-cell responds to changes in the nutrient environment to maintain glucose homeostasis by adapting its function and mass. Nutrients can act directly on the β-cell and also indirectly through the brain via autonomic nerves innervating islets. Despite the importance of the brain-islet axis in insulin secretion, relatively little is known regarding its involvement in β-cell proliferation. We previously demonstrated that prolonged infusions of nutrients in rats provoke a dramatic increase in β-cell proliferation in part because of the direct action of nutrients. Here, we addressed the contribution of the autonomic nervous system. In isolated islets, muscarinic stimulation increased, whereas adrenergic stimulation decreased, glucose-induced β-cell proliferation. Blocking α-adrenergic receptors reversed the effect of epinephrine on glucose + nonesterified fatty acids (NEFA)-induced β-cell proliferation, whereas activation of α-adrenergic receptors was without effect. Infusion of glucose + NEFA toward the brain stimulated β-cell proliferation, and this effect was abrogated following celiac vagotomy. The increase in β-cell proliferation following peripheral infusions of glucose + NEFA was not inhibited by vagotomy or atropine treatment but was blocked by coinfusion of epinephrine. We conclude that β-cell proliferation is stimulated by parasympathetic and inhibited by sympathetic signals. Whereas glucose + NEFA in the brain stimulates β-cell proliferation through the vagus nerve, β-cell proliferation in response to systemic nutrient excess does not involve parasympathetic signals but may be associated with decreased sympathetic tone. [ABSTRACT FROM AUTHOR]

Ββ-Cell adaptation to insulin resistance is necessary to maintain glucose homeostasis in obesity. Failure of this mechanism is a hallmark of type 2 diabetes (T2D). Hence, factors controlling functional β-cell compensation are potentially important targets for the treatment of T2D. Protein kinase D1 (PKD1) integrates diverse signals in the β-cell and plays a critical role in the control of insulin secretion. However, the role of β-cell PKD1 in glucose homeostasis in vivo is essentially unknown. Using β-cell-specific, inducible PKD1 knockout mice (βPKD1KO), we examined the role of β-cell PKD1 under basal conditions and during high-fat feeding. βPKD1KO mice under a chow diet presented no significant difference in glucose tolerance or insulin secretion compared with mice expressing the Cre transgene alone; however, when compared with wild-type mice, both groups developed glucose intolerance. Under a high-fat diet, deletion of PKD1 in β-cells worsened hyperglycemia, hyperinsulinemia, and glucose intolerance. This was accompanied by impaired glucose-induced insulin secretion both in vivo in hyperglycemic clamps and ex vivo in isolated islets from high-fat diet-fed βPKD1KO mice without changes in islet mass. This study demonstrates an essential role for PKD1 in the β-cell adaptive secretory response to high-fat feeding in mice. [ABSTRACT FROM AUTHOR]

The mechanisms underlying the generation of neural cell diversity are the subject of intense investigation, which has highlighted the involvement of different signalling molecules including Shh, BMP and Wnt. By contrast, relatively little is known about FGF in this process. In this report we identify an FGF-receptor-dependent pathway in zebrafish hindbrain neural progenitors that give rise to somatic motoneurons, oligodendrocyte progenitors and differentiating astroglia. Using a combination of chemical and genetic approaches to conditionally inactivate FGF-receptor signalling, we investigate the role of this pathway. We show that FGF-receptor signalling is not essential for the survival or maintenance of hindbrain neural progenitors but controls their fate by coordinately regulating key transcription factors. First, by cooperating with Shh, FGF-receptor signalling controls the expression of olig2, a patterning gene essential for the specification of somatic motoneurons and oligodendrocytes. Second, FGF-receptor signalling controls the development of both oligodendrocyte progenitors and astroglia through the regulation of sox9, a gliogenic transcription factor the function of which we show to be conserved in the zebrafish hindbrain. Overall, for the first time in vivo, our results reveal a mechanism of FGF in the control of neural cell diversity. [ABSTRACT FROM AUTHOR]

In nondiabetic obese individuals, β-cell mass accretion maintains glucose homeostasis by balancing levels of circulating insulin and insulin resistance. Type 2 diabetes appears when these compensatory mechanisms fail. Deciphering the pathways controlling β-cell proliferation may help to identify therapeutic targets to expand β-cell mass and prevent or delay the onset of diabetes. Previously we demonstrated that the monounsaturated fatty-acid oleate potentiates glucose-induced rat β-cell proliferation. Aim: To identify the transcriptional mechanisms underlying oleate-induced rat β-cell proliferation. Methods: Rat islets were exposed to 16.7mM glucose (Glu) with or without 0.5 mM oleate (Glu+Ol) or palmitate (Glu+Pal) for 48h. Proliferation was assessed by flow cytometry (C-peptide staining and EdU incorporation). Single-cell cDNA libraries were generated using 10X Genomics technology and sequenced on the Illumina platform. Bioinformatic analyses were performed using Seurat package. Results: β-cell proliferation was potentiated by Ol, but not Pal. Following single-cell RNA sequencing, UMAP plots revealed several β-cell sub-populations, including proliferating β-cells. A number of differences in gene expression were identified between groups in non-proliferating sub-populations. Among these, gene sets involved in ER-stress and β-cell differentiation were significantly up- and down-regulated, respectively, in response to Pal, but not Ol. Gene set enrichment analyses comparing proliferative vs. non-proliferative β-cells revealed an up-regulation of reactive oxygen species (ROS) and oxidoreductase activity-related pathways in both Glu and Glu+Ol groups. The antioxidant N-acetyl cysteine or the peroxiredoxin inhibitor Conoidin A inhibited Glu+Ol-induced β-cell proliferation. Conclusion: Our results suggest the involvement of ROS signaling through a redox relay via peroxiredoxin activation in nutrient-induced β-cell proliferation. Disclosure: A. Vivoli: None. J. Ghislain: None. A. Castell: None. A. Filali: None. R. M. Sladek: None. V. Poitout: None. [ABSTRACT FROM AUTHOR]

Background: In nondiabetic obese individuals, β-cell mass accretion maintains glucose homeostasis by balancing levels of circulating insulin and insulin resistance. Type 2 diabetes appears when these compensatory mechanisms fail. Deciphering the pathways controlling β-cell proliferation has thus become a major research goal in the hope to identify therapeutic targets to expand β-cell mass and prevent or delay the onset of diabetes. Previously we demonstrated that fatty acids potentiate glucose induced β-cell proliferation in response to nutrient surfeit in rats. In recent studies we identified the mono-unsaturated fatty-acid oleate as a major fatty acid driving β-cell proliferation in rat islets ex vivo. Aim: To identify the transcriptional mechanisms underlying oleate-induced β-cell proliferation in rats. Method: Rat islets were exposed to 16.7mM glucose +/- oleate (0.5mM) for 48h. Proliferation was assessed by flow cytometry using c-peptide antibodies and EdU. Single cell cDNA libraries were generated using 10X Genomics technology and sequenced on the Illumina platform. Bioinformatic analyses were performed using the Cell Ranger pipeline, Seurat and Monocle. Results: Oleate induced a 3.1+/-0.4 fold increase (p<0.01; n=4) in β-cell proliferation. Following single-cell RNA sequencing, t-SNE plots revealed several β-cell sub-populations, including proliferating β-cells. Comparison between proliferative and non-proliferative β-cells identified more than 300 differentially expressed genes. Gene ontology suggested an increase in mitochondrial activity and reactive oxygen species (ROS) in proliferating β-cells. Pseudotime ordering of β cells revealed that ER-stress related genes are up-regulated prior to proliferation in response to oleate. Conclusion: Our study suggests an involvement of ROS and ER-stress in oleate-induced β-cells proliferation. Further functional analyses will substantiate the importance of these stress responses. Disclosure: A. Vivoli: None. A. Castell: None. A. Pacis: None. R.M. Sladek: None. J. Ghislain: None. V. Poitout: None. [ABSTRACT FROM AUTHOR]

Puberty is a time of hormonal changes associated with insulin resistance (IR). Although insulin sensitivity is restored at the end of puberty in healthy youth, it does not resolve in obese adolescents leading to an increased risk of metabolic disease such as T2D. During pregnancy-induced IR, pancreatic β cells increase their functional mass to maintain glucose homeostasis. During puberty, however, the mechanism of β-cell compensation to IR and its role in glucose metabolism in adulthood have not been established. In this study we characterized pancreatic β-cell adaptation to pubertal IR in rats and evaluated the effect of metabolic stress during puberty on glucose homeostasis in adult animals. Methods: Wistar rats were fed a chow or high fat diet (HFD) during puberty. Fasted plasma insulin and glucose tolerance were determined from weaning to adulthood. β-cell proliferation was assessed by immunostaining of pancreatic cryosections for Ki67 and insulin or Nkx6.1. β-cell mass was measured by morphometric analysis of insulin staining. Isolated islets from Wistar rats were exposed during 72h to the serum of prepubertal, pubertal, or postpubertal animals and β-cell proliferation was evaluated by flow cytometry using insulin and EdU antibodies. Results: During puberty, glucose intolerance was associated with an increase in insulin levels, suggestive of IR. Accordingly, puberty was characterized by a pulse in β-cell proliferation and a rise in β-cell mass. Pubertal but not pre or post pubertal rat serum induced β-cell proliferation in isolated islets. HFD led to a decrease in β-cell proliferation during puberty with impaired glucose tolerance and defective insulin secretion in adult animals. Conclusion: During puberty in rats, β cells proliferate to compensate for IR. Metabolic stress during puberty impairs glucose homeostasis later in life. Future studies will identify the circulating factor(s) that trigger β-cell expansion during puberty. Disclosure: A. Castell: None. G. Fergusson: None. M. Ethier: None. C. Tremblay: None. J. Ghislain: None. V. Poitout: None. [ABSTRACT FROM AUTHOR]

Background: Glucose is a major β-cell mitogen. Despite recent progress, the underlying mechanisms remain unclear. In a rat model of nutrient excess we previously showed that nutrient-induced β-cell proliferation is blocked when either EGF receptor (EGFR) or mTOR signaling is inhibited. Parallel transcriptomic analyses identified the EGFR ligand, HB-EGF as a potential mediator of nutrient-induced β-cell proliferation. Objective: To determine the role of HB-EGF in glucose-induced β-cell proliferation. Methods: HB-EGF mRNA levels were assessed by real-time PCR in isolated rat islets following a 24-h exposure to 2.8 or 16.7 mM glucose. The Carbohydrate-Responsive Element-Binding Protein (ChREBP) transcription factor was down-regulated by siRNA in dispersed rat islets. For β-cell proliferation studies islets were exposed to 16.7 mM glucose or HB-EGF (100 ng/ml) in the presence of 2.8 mM glucose for 72 h. Islets were co-cultured with the EGFR inhibitor AG1478 (300 nM) or the HB-EGF inhibitor CRM197 (10 ug/ml). shRNA was used to knockdown HB-EGF in isolated islets and either cultured ex vivo or transplanted under the kidney capsule of glucose-infused rats. β-cell proliferation was assessed by immunohistochemistry for Ki67 and insulin. Results: Glucose increased HB-EGF mRNA levels and this was prevented by ChREBP knockdown. HB-EGF potently stimulated β-cell proliferation. Inhibition of the EGFR or HB-EGF completely blocked not only the proliferative response to HB-EGF but also the response to 16.7 mM glucose. Knockdown of HB-EGF blocked the β-cell proliferative response to glucose in isolated rat islets as well as in transplanted islets. Conclusion: HB-EGF is a potent β-cell mitogen in rat islets. Glucose increases HB-EGF gene expression via ChREBP. The proliferative response to glucose requires an intact HB-EGF - EGFR pathway. Our findings identify a novel player in the complex mechanisms controlling β-cell proliferation in response to glucose. Disclosure: H. Maachi: None. D. Scott: None. J. Ghislain: None. V. Poitout: None. Funding: National Institutes of Health; Fonds de recherche du Québec-Santé [ABSTRACT FROM AUTHOR]

Fatty acids (FA) are major regulators of pancreatic β-cell function. In a rat model of nutrient excess we previously showed that FA potentiate glucose-induced β-cell proliferation. Sphingolipids, derived from the intracellular metabolism of FA, act as cellular mediators in the regulation of pancreatic β-cell function. However, the contribution of sphingolipid species to FA-induced β-cell proliferation is unknown. Objective: To determine the role of de novo sphingolipid synthesis in FA-induced β-cell proliferation. Methods: Isolated rat islets were exposed to oleate or palmitate (0.5 mM) in the presence of 16.7 mM glucose for 48h. Sphingosine kinase (SphK) 1 and 2 expression was measured by real-time PCR. Serine palmitoyl transferase (SPT), SphK, and the S1P3 receptor were inhibited with Myriocin, SKI II and TY52156, respectively. β-cell proliferation was assessed in cryosections by immunohistochemical detection of insulin and the proliferation marker Ki67 or by flow cytometry by labeling for C-peptide and EdU incorporation. Wistar rats were infused for 72 hours with glucose and a lipid emulsion (CLI) to induce β-cell proliferation. Results: The monounsaturated FA oleate, but not the saturated FA palmitate, increased β-cell proliferation. Blocking de novo sphingolipid synthesis by SPT inhibition decreased oleate-induced β-cell proliferation as did inhibition of SphK and S1P3 receptor activation. Sphk1/2 mRNA levels in islets were not significantly changed following nutrient infusion in rats or FA exposure ex vivo. Conclusion: β-cell proliferation in response to oleate requires de novo sphingolipid synthesis and S1P3 signaling. Analyses are underway to assess the contribution of SphK products sphingosine-1-phosphate and dihydrosphinganine-1-phosphate in S1P3-mediated β-cell proliferation. Disclosure: A. Castell: None. A. Vivoli: None. V.S. Moullé: None. J. Ghislain: None. V. Poitout: None. Funding: National Institutes of Health; Canadian Institutes of Health Research [ABSTRACT FROM AUTHOR]

Background: Puberty is a time of hormonal changes that are associated with insulin resistance (IR). Although insulin sensitivity is restored at the end of puberty in healthy youth, it does not resolve in obese adolescents leading to an increased risk of metabolic disease such as type 2 diabetes. In pregnancy and obesity-induced IR, β-cells increase their functional mass to maintain glucose homeostasis. During puberty, however, the mechanism of pancreatic β-cell compensation to IR and its role in glucose metabolism later in life have not been established. Objective: To characterize pancreatic β-cell adaptation to pubertal IR in rats and study the effect of metabolic stress during puberty on glucose homeostasis in adult animals. Methods: Male and female Wistar rats were fed a chow diet or a high fat diet (HFD) during puberty. Body weight, fasted plasma insulin, glucose tolerance and hormone levels (estradiol, testosterone, insulin growth factor-1 (IGF1), growth hormone (GH)) were determined every 5 days from weaning to adulthood. β-cell proliferation was assessed by immunostaining of pancreatic cryosections for Ki67 and insulin to mark β-cells and β-cell mass by morphometric analysis of insulin staining. Results: During puberty, glucose intolerance was associated with an increase in insulin levels in both sexes, suggestive of IR. Correspondingly, β-cell proliferation increased, as did islet size and β-cell mass. β-cell expansion correlated with a rise in IGF1/GH levels. HFD during puberty impaired glucose tolerance in adults. Conclusion: During puberty in rats, β-cells compensate for increased IR. Metabolic stress during puberty impairs glucose homeostasis later in life. Future studies will address whether β-cell expansion during puberty is under control of the IGF1/GH axis. Disclosure: A. Castell: None. M. Ethier: None. G. Fergusson: None. J. Ghislain: None. V. Poitout: None. Funding: National Institutes of Health; Societé Francaise d'Endocrinologie Diabetologie Pediatrique [ABSTRACT FROM AUTHOR]

Gpr120 is a long-chain fatty acid receptor expressed in pancreatic islets, where it inhibits the secretion of somatostatin (SST) by the δ cell. SST is a negative regulator of glucoregulatory hormone secretion. However, the precise role of Gpr120 in the regulation of insulin and glucagon secretion is still unclear, as well as the specific islet cell(s) type(s) involved. Objective: This study aimed at defining the role of pancreatic δ-cell Gpr120 signaling in the regulation of islet function and glucose homeostasis. Methods: Insulin and SST secretion was measured in isolated islets from WT, Gpr120 KO and Gpr40 KO mice in 1h static incubation in the presence of 2.8 or 16.7 mM glucose with or without synthetic (Compound A, Cpd A) or endogenous (alpha-linolenic, eicosapentaenoic or docosahexaenoic acid) Gpr120 agonists. Glucagon and SST secretion was measured after 1h static incubation in response to arginine with or without Cpd A. Cpd A was administered orally to WT male mice before an oral Glucose Tolerance Test or an Arginine Test, and blood glucose and insulin or glucagon plasma levels were measured. Results: In isolated islets from WT mice, activation of Gpr120 with either Cpd A or endogenous agonists dose-dependently inhibited glucose-stimulated SST secretion, and concomitantly increased glucose-stimulated insulin secretion. Cpd A also inhibited SST secretion and potentiated glucagon secretion in response to arginine in low glucose conditions. The effects of Cpd A were unaltered in Gpr40 KO islets but disappeared in Gpr120 KO islets. Oral administration of Cpd A improved glucose tolerance and potentiated both glucose-induced insulin secretion and arginine-induced glucagon secretion. Conclusion: The results demonstrate that Gpr120 activation in islets inhibits SST secretion, potentiates insulin and glucagon secretion, and improves glycemic control. Disclosure: M.L. Croze: None. S. Granziera: None. K. Vivot: None. A. Szpigel: None. J. Ghislain: None. V. Poitout: None. Funding: Société Francophone du Diabète; Montreal Diabetes Research Center; Natural Sciences and Engineering Research Council of Canada [ABSTRACT FROM AUTHOR]

Background: The free-fatty acid receptor-1 (FFA-1) is expressed by β-cells and is a promising target for molecular imaging of functional β-cell mass. Recently, the ((3-[18F]fluoropropyl)sulfonyl)propoxy-derivative of the high-affinity FFA-1 agonist TAK-875 ([18F]7) was reported. Here we describe the preparation of this tracer in high molar activity using a purification method permitting separation of [18F]7 from a structurally-related by-product and evaluation of the tracer in rats as a potential FFA-1 PET imaging agent.Results: The radiotracer was produced by nucleophilic radio-fluorination of the tosylate precursor and deprotection of the methyl ester. Semi-preparative HPLC with a C18 column revealed that [18F]7 co-eluted with a non-radioactive impurity. Mass spectrometry identified the impurity as the alkene-containing elimination by-product. A pentafluorophenyl-functionalized HPLC column was found to separate the two compounds and allowed for purification of [18F]7 in high molar activity. A strong anion-exchange resin was used to reformulate [18F]7 in high concentration. Starting from 96 to 311 GBq of [18F]fluoride, 3.8-15.4 GBq of pure [18F]7 (end of synthesis (EOS)) was prepared (RCY 8.3% ± 1.1% decay-corrected, n = 4) in high molar activity (166-767 GBq/μmol at EOS). This PET agent was evaluated in rats using dynamic microPET/CT imaging, ex vivo biodistribution, and radio-metabolite studies. MicroPET/CT exhibited high uptake of the tracer in the abdominal area. There was no measurable decrease of the PET signal in the pancreatic area in rats pre-treated with saturating doses (30 mg/kg) of TAK-875. Biodistribution studies corroborated the microPET/CT results. Radiometabolism analyses revealed high compound stability with only the parent molecule detected in the pancreas.Conclusions: Analysis of the crude reaction mixture and identification of the elimination by-product allowed for the development of a fully automated process to prepare the TAK-875-derived PET agent [18F]7 in high purity and high molar activity. Even though the radiotracer exhibited high in vivo stability, microPET/CT and biodistribution results confirmed recent reports demonstrating that lipophilic analogs of TAK-875 display a high degree of non-specific binding, masking any specific binding to FFA-1 in pancreatic β-cells. Future development of TAK-875-derived PET tracers should focus on reducing non-specific binding in the pancreatic tissue. [ABSTRACT FROM AUTHOR]

The morphogenesis of the vertebrate hindbrain involves the generation of metameric units called rhombomeres (r), and Krox20 encodes a transcription factor that is expressed in r3 and r5 and plays a major role in this segmentation process. Our knowledge of the basis of Krox20 regulation in r3 is rather confusing, especially concerning the involvement of Hox factors. To investigate this issue, we studied one of the Krox20 hindbrain cis-regulatory sequences, element C, which is active in r3-r5 and which is the only initiator element in r3. We show that element C contains multiple binding sites for Meis and Hox/Pbx factors and that these proteins synergize to activate the enhancer. Mutation of these binding sites allowed us to establish that Krox20 is under the direct transcriptional control of both Meis (presumably Meis2) and Hox/Pbx factors in r3. Furthermore, our data indicate that element C functions according to multiple modes, in Meis-independent or -dependent manners and with different Hox proteins, in r3 and r5. Finally, we show that the Hoxb1 and Krox20 expression domains transiently overlap in prospective r3, and that Hoxb1 binds to element C in vivo, supporting a cell-autonomous involvement of Hox paralogous group 1 proteins in Krox20 regulation. Altogether, our data clarify the molecular mechanisms of an essential step in hindbrain patterning. We propose a model for the complex regulation of Krox20, involving a novel mode of initiation, positive and negative controls by Hox proteins, and multiple direct and indirect autoregulatory loops. [ABSTRACT FROM AUTHOR]

Onset of myelination in Schwann cells is governed by several transcription factors, including Krox20/Egr2, and mutations affecting Krox20 result in various human hereditary peripheral neuropathies, including congenital hypomyelinating neuropathy (CHN) and Charcot-Marie-Tooth disease (CMT). Similar molecular information is not available on the process of myelin maintenance. We have generated conditional Krox20 mutations in the mouse that allowed us to develop models for CHN and CMT. In the latter case, specific inactivation of Krox20 in adult Schwann cells results in severe demyelination, involving rapid Schwann cell dedifferentiation and increased proliferation, followed by an attempt to remyelinate and a block at the promyelinating stage. These data establish that Krox20 is not only required for the onset of myelination but that it is also crucial for the maintenance of the myelinating state. Furthermore, myelin maintenance appears as a very dynamic process in which Krox20 may constitute a molecular switch between Schwann cell myelination and demyelination programs. [ABSTRACT FROM AUTHOR]

The vertebrate hindbrain is subject to a transient segmentation process leading to the formation of seven or eight metameric territories termed rhombomeres (r). This segmentation provides the basis for the subsequent establishment of hindbrain neuronal organization and participates in the patterning of the neural crest involved in craniofacial development. The zinc-finger gene Krox20 is expressed in r3 and r5, and encodes a transcription factor that plays a key role in hindbrain segmentation, coordinating segment formation, specification of odd- and even-numbered rhombomeres, and cell segregation between adjacent segments, through the regulation of numerous downstream genes. In order to further elucidate the genetic network underlying hindbrain segmentation, we have undertaken the analysis of the cis-regulatory sequences governing Krox20 expression. We have found that the control of Krox20 transcription relies on three very long-range (200 kb) enhancer elements (A, B and C) that are conserved between chick, mouse and human genomes. Elements B and C are activated at the earliest stage of Krox20 expression in r5 and r3-r5, respectively, and do not require the Krox20 protein. These elements are likely to function as initiators of Krox20 expression. Element B contains a binding site for the transcription factor vHNF1, the mutation of which abolishes its activity, suggesting that vHNF1 is a direct initiator of Krox20 expression in r5. Element A contains Krox20-binding sites, which are required, together with the Krox20 protein, for its activity. This element therefore allows the establishment of a direct positive autoregulatory loop, which takes the relay of the initiator elements and maintains Krox20 expression. Together, our studies provide a basis for a model of the molecular mechanisms controlling Krox20 expression in the developing hindbrain and neural crest. [ABSTRACT FROM AUTHOR]

Puberty is associated with transient insulin resistance that normally recedes at the end of puberty; however, in overweight children, insulin resistance persists, leading to an increased risk of type 2 diabetes. The mechanisms whereby pancreatic β cells adapt to pubertal insulin resistance, and how they are affected by the metabolic status, have not been investigated. Here, we show that puberty is associated with a transient increase in β cell proliferation in rats and humans of both sexes. In rats, β cell proliferation correlated with a rise in growth hormone (GH) levels. Serum from pubertal rats and humans promoted β cell proliferation, suggesting the implication of a circulating factor. In pubertal rat islets, expression of genes of the GH/serotonin (5-hydroxytryptamine [5-HT]) pathway underwent changes consistent with a proliferative effect. Inhibition of the pro-proliferative 5-HT receptor isoform HTR2B blocked the increase in β cell proliferation in pubertal islets ex vivo and in vivo. Peripubertal metabolic stress blunted β cell proliferation during puberty and led to altered glucose homeostasis later in life. This study identifies a role of GH/GH receptor/5-HT/HTR2B signaling in the control of β cell mass expansion during puberty and identifies a mechanistic link between pubertal obesity and the risk of developing type 2 diabetes.

Of the 415 million people suffering from diabetes worldwide, 90% have type 2 diabetes. Type 2 diabetes is characterized by hyperglycemia and occurs in obese individuals as a result of insulin resistance and inadequate insulin levels. Accordingly, diabetes drugs are tailored to enhance glucose disposal or target the pancreatic islet β cell to increase insulin secretion. The majority of the present-day insulin secretagogues, however, increase the risk of iatrogenic hypoglycemia, and hence alternatives are actively sought. The long-chain fatty acid, G protein-coupled receptor FFA1/Gpr40, is expressed in β cells, and its activation potentiates insulin secretion in a glucose-dependent manner. Preclinical data indicate that FFA1 agonism is an effective treatment to restore glucose homeostasis in rodent models of diabetes. This initial success prompted clinical trials in type 2 diabetes patients, the results of which were promising; however, the field suffered a significant setback when the lead compound TAK-875/fasiglifam was withdrawn from clinical development due to liver safety concerns. Nevertheless, recent developments have brought to light a surprising complexity of FFA1 agonist action, signaling diversity, and biological outcomes, raising hopes that with a greater understanding of the mechanisms at play the second round will be more successful.

Free fatty acid receptor 1 (FFA1/GPR40) plays a key role in the potentiation of glucose-stimulated insulin secretion by fatty acids in pancreatic β cells. We previously demonstrated that GPR40 signaling leads to cortical actin remodeling and potentiates the second phase of insulin secretion. In this study, we examined the role of p21 activated kinase 4 (PAK4), a known regulator of cytoskeletal dynamics, in GPR40-dependent potentiation of insulin secretion. The fatty acid oleate induced PAK4 phosphorylation in human islets, in isolated mouse islets and in the insulin secreting cell line INS832/13. However, oleate-induced PAK4 phosphorylation was not observed in GPR40-null mouse islets. siRNA-mediated knockdown of PAK4 in INS832/13 cells abrogated the potentiation of insulin secretion by oleate, whereas PAK7 knockdown had no effect. Our results indicate that PAK4 plays an important role in the potentiation of insulin secretion by fatty acids downstream of GPR40.

Neural crest patterning constitutes an important element in the control of the morphogenesis of craniofacial structures. Krox20, a transcription factor gene that plays a critical role in the development of the segmented hindbrain, is expressed in rhombomeres (r) 3 and 5 and in a stream of neural crest cells migrating from r5 toward the third branchial arch. We have investigated the basis of the specific neural crest expression of Krox20 and identified a cis-acting enhancer element (NCE) located 26 kb upstream of the gene that is conserved between mouse, man and chick and can recapitulate the Krox20 neural crest pattern in transgenic mice. Functional dissection of the enhancer revealed the presence of two conserved Krox20 binding sites mediating direct Krox20 autoregulation in the neural crest. In addition, the enhancer included another essential element containing conserved binding sites for high mobility group (HMG) box proteins and which responded to factors expressed throughout the neural crest. Consistent with this the NCE was strongly activated in vitro by Sox10, a crest-specific HMG box protein, in synergism with Krox20, and the inactivation of Sox10 prevented the maintenance of Krox20 expression in the migrating neural crest. These results suggest that the dependency of the enhancer on both crest- (Sox10) and r5- (Krox20) specific factors limits its activity to the r5-derived neural crest. This organisation also suggests a mechanism for the transfer and maintenance of rhombomere-specific gene expression from the hindbrain neuroepithelium to the emerging neural crest and may be of more general significance for neural crest patterning.

In Schwann cells (SC), myelination is controlled by the transcription factor gene Krox20/Egr2. Analysis of cis-acting elements governing Krox20 expression in SC revealed the existence of two separate elements. The first, designated immature Schwann cell element (ISE), was active in immature but not myelinating SC, whereas the second, designated myelinating Schwann cell element (MSE), was active from the onset of myelination to adulthood in myelinating SC. In vivo sciatic nerve regeneration experiments demonstrated that both elements were activated during this process, in an axon-dependent manner. Together the activity of these elements reproduced the profile of Krox20 expression during development and regeneration. Genetic studies showed that both elements were active in a Krox20 mutant background, while the activity of the MSE, but likely not of the ISE, required the POU domain transcription factor Oct6 at the time of myelination. The MSE was localised to a 1.3 kb fragment, 35 kb downstream of Krox20. The identification of multiple Oct6 binding sites within this fragment suggested that Oct6 directly controls Krox20 transcription. Taken together, these data indicate that, although Krox20 is expressed continuously from 15.5 dpc in SC, the regulation of its expression is a biphasic, axon-dependent phenomenon involving two cis-acting elements that act in succession during development. In addition, they provide insight into the complexity of the transcription factor regulatory network controlling myelination.